Positive New Data From Phase 1/2 Trial of AT-01 (Iodine I-124 Evuzamitide) Presented at 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced encouraging new clinical data from the University of Tennessee Graduate School of Medicine from its Phase 1/2 trial of AT-01 (Iodine I-124 evuzamitide), the company’s pan-amyloid binding peptide in development as a radiotracer for the diagnosis of multiple types of systemic amyloidosis. These data were included in oral and poster presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting taking place June 11-14, 2022, in Vancouver, BC, Canada.

The Phase 1/2 trial evaluated the ability of AT-01 to detect amyloid deposits by PET/CT imaging in patients with diverse types of systemic amyloidosis. The study enrolled a total of 57 subjects, 50 of which had systemic amyloidosis, two of which were asymptomatic ATTR carriers, and five of which were healthy volunteers.